Shionogi’s H1 Sales Wane 2.3% as Crestor Royalties Almost Disappear

Shionogi saw its first-half revenue fall 2.3% year on year as Crestor (rosuvastatin) royalties decreased to nearly zero under its license agreement with AstraZeneca, which weighed on the topline to offset the positive impact of strong pharma sales in Japan...read more